Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children

The European Respiratory Journal
F M de BenedictisA Capristo

Abstract

The effect over time of regular treatment with montelukast (MNT) in inhibiting exercise-induced bronchoconstriction (EIB) has never been evaluated in children. The aim of the present study was to examine the preventive effect of MNT against EIB in children at different time-points over a 4-week treatment period. Thirty-two asthmatic children (aged 6-12 yrs) were enrolled in a double-blinded, randomised, parallel group design to receive a 4-week treatment with MNT (5 mg chewable tablets administered once daily in the evening) or placebo. Exercise challenge was performed at baseline and after 3, 7 and 28 days of treatment, 20-24 h after dosing. MNT was significantly more protective than placebo against EIB at each time. The mean percentage drop of forced expiratory volume in one second (FEV1) was 24.6, 13.6, 12.0 and 11.6 for MNT, and 24.4, 22.4, 21.8 and 21.0 for placebo, at baseline and after 3, 7 and 28 days, respectively. For each drug, no significant difference in the percentage drop of FEV1 was found between different days. Regular treatment with montelukast provided significant protection against exercise-induced bronchoconstriction in asthmatic children over a 4-week period with no tolerance to the bronchoprotective effect.

Citations

Jun 30, 2009·Advances in Therapy·Jean BousquetMarc Humbert
Jun 28, 2012·Italian Journal of Pediatrics·Silvia MontellaFrancesca Santamaria
Apr 2, 2008·Medicine and Science in Sports and Exercise·Maria R BonsignoreGiuseppe Morici
Jan 1, 2009·Journal of Asthma and Allergy·Terrence W Carver
Dec 17, 2009·Therapeutics and Clinical Risk Management·James P Kemp
Nov 3, 2009·Annals of Thoracic Medicine·Mohamed S Al-MoamaryMaha Al Dabbagh
May 19, 2010·Expert Review of Clinical Immunology·Zuzana DiamantLeif Bjermer
Mar 1, 2009·Expert Review of Clinical Immunology·So-Yeon LeeSoo-Jong Hong
Oct 7, 2010·Expert Review of Respiratory Medicine·Kanami OriharaRedwan Moqbel
Jun 28, 2011·Expert Review of Respiratory Medicine·Jimmi ElersVibeke Backer
Jul 9, 2013·Immunology and Allergy Clinics of North America·Vibeke BackerCeleste Porsbjerg
Jan 5, 2011·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·John M WeilerUNKNOWN Joint Council of Allergy, Asthma and Immunology
Jun 24, 2010·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Robert B FogelPeter G Polos
Nov 6, 2007·The Journal of Allergy and Clinical Immunology·Iwona StelmachPiotr Kuna
Dec 7, 2007·Allergy·L B BacharierUNKNOWN European Pediatric Asthma Group
Jul 10, 2013·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Yves PachecoGilles Devouassoux
Aug 26, 2011·Respiratory Medicine·Diego G PeroniGiorgio L Piacentini
Sep 26, 2016·The Journal of Allergy and Clinical Immunology·John M WeilerDana Wallace
Mar 5, 2008·Current Opinion in Allergy and Clinical Immunology·Kai-Håkon Carlsen, Karin C L Carlsen
Apr 8, 2017·Expert Opinion on Pharmacotherapy·Carolina VitaleAlessandro Vatrella
Oct 14, 2009·Therapeutic Advances in Respiratory Disease·Michele Miraglia del GiudiceAngelo F Capristo
Oct 28, 2011·The Physician and Sportsmedicine·Lars PedersenVibeke Backer
Dec 15, 2016·Asthma Research and Practice·Cottini Marcello, Lombardi Carlo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.